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Abstract
Background: Metformin has been used for the treatment of type 2 diabetes by suppressing hepatic
gluconeogenesis. It has been shown that the subclinical inflammatory responses play important roles in the
pathogenesis of type 2 diabetes. In the present study, we determined the effects of metformin on the levels of
pro-inflammatory cytokines (i.e., IL-6, TNF-α, and MCP-1) and anti-inflammatory mediator IL-10 in blood and urine
of patients with type 2 diabetes. There were 210 patients with type 2 diabetes, which were randomized into
metformin (n = 112) and non-metformin (gliclazide, acarbose, and repaglinide, n = 98) groups. The levels of
cytokines were measured by the ELISA.
Results: We found that metformin reduced the levels of IL-6 in blood and MCP-1 in urine, but increased IL-10
levels in blood of patients with type 2 diabetes. There were no significant differences of TNF-α between metformin
and non-metformin groups. Furthermore, compared to individual drug treatment, metformin significantly reduced
the levels of serum IL-6 and TNF-α, as well as urine MCP-1. When the patients were stratified based on the
durations and doses of metformin, we found that there was only change (i.e., increase) in serum IL-10 levels in
patients with metformin for more than 1 year compared to treatment for less than 1 year. Metformin (1.5 g)
treatment reduced the urinary levels of MCP-1 as compared with dose of 1.0 g in patients with type 2 diabetes.
Conclusion: Metformin reduces inflammatory responses without influence on renal function in type 2 diabetic
patients.
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Background
Diabetes mellitus is a metabolic disease, which is charac-
terized by the hyperglycemia due to either insulin insuffi-
ciency or resistance. There are more than 90% cases with
type 2 diabetes where the cells in the body show reduced
reaction to insulin (insulin resistance). Diabetes is the sev-
enth most common cause of death in the United States,
and it causes a variety of health complications including
heart disease, blindness, kidney failure, and lower-
extremity amputations. Numerous pathogenic processes
are implicated in the development of diabetes, which re-
sult from the β-cell destruction in the pancreas leading to
insulin deficiency or from the abnormalities that cause
insulin resistance in target tissues [1, 2]. The abnormal in-
flammatory responses have been shown to play important
roles in the pathogenesis and progression of type 2 dia-
betes [3–5]. For instance, pro-inflammatory cytokines in-
cluding interleukin (IL)-6 and tumor necrosis factor
(TNF)-α enhance insulin resistance, and are associated
with increased risk of type 2 diabetes [6–9]. In contrast,
IL-10, an anti-inflammatory cytokine, is reduced in pa-
tients with type 2 diabetes [10]. Therefore, the therapeutic
treatments with anti-inflammatory properties would be
beneficial to the management of type 2 diabetes.
Metformin is the first-line therapy for the treatment
of type 2 diabetes by repressing the hepatic gluconeo-
genesis [11–13]. The molecular mechanism of metfor-
min is associated with the activation of AMP-activated
protein kinase (AMPK) and protein kinase A (PKA) as
well as the inhibition of the mitochondrial respiratory
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chain (complex I) and glycerophosphate dehydrogenase.
It has been suggested that metformin improves meta-
bolic parameters such as hyperglycemia, insulin resist-
ance and atherogenic dyslipidemia, thereby reducing
chronic inflammatory responses [14, 15]. However, it is
not clear whether metformin has any effects on inflam-
matory responses in the systemic circulation and urine
of patients with type 2 diabetes. In the present study,
we determined the effects of metformin with different
doses and durations on the levels of pro-inflammatory
cytokines (i.e., IL-6, TNF-α, and MCP-1) and anti-
inflammatory mediator IL-10 in blood and urine of pa-
tients with type 2 diabetes.
Methods
Patient enrollment
There were 210 patients diagnosed with type 2 dia-
betes during the period of January 2015 to December
2015 in the Anhui Provincial Hospital. The character-
istics of these patients were shown in Table 1. The
criteria for patient inclusion were shown as the fol-
lowing: 1) All patients are diagnosed according to the
WHO diagnostic guidelines (1999 version) for type 2
diabetes; 2) ages are between 42 and 70; 3) 4.8% ≤ gly-
cated hemoglobin A1c ≤ 7.5%. The criteria for patient
exclusion were described as the following: 1) Patients
with acute infection in past two months; 2) Any sys-
temic immune disorders; 3) Chronic infectious dis-
eases and tumors; 4) Surgical operation within last
three months; 5) Severe hepatic and kidney dysfunc-
tion; and 6) Extremely high blood pressure.
Metformin and other anti-diabetic medications
All these 210 patients with type 2 diabetes were ran-
domly divided into metformin (n = 112) and non-
metformin (n = 98) groups. For the metformin group,
patients received metformin (1000 mg or 1500 mg) daily
through oral administration. For the non-metformin
group, patients received one of the following drugs: gli-
clazide (a sulfonylurea, n = 44), acarbose (a glucosidase
inhibitor, n = 18), and repaglinide (stimulating the release
of insulin, n = 36) for 12 months.
Measurement of cytokine by ELISA
Serum was obtained from patient venous blood
through centrifugation for 10 min at 1500 rpm. Simi-
larly, the urine was collected followed by the centrifu-
gation, and kept at −80 °C until analysis. The levels of
IL-6, IL-10 and TNF-α in serum and monocyte
chemoattractant protein-1 (MCP-1) in urine were
measured using the corresponding ELISA kits from
R&D Systems (Minneapolis, MN, USA) according the
manufacturer’s protocols.
Statistics
All statistical analysis was performed by the Graphpad
Prism software, and the differences between two groups
(e.g., metformin vs every treatment) were compared using a
Dunnett’s post-hoc test following an ANOVA.
Results
Biochemical characteristics between metformin and non-
metformin groups
As shown in Table 1, there was no significant difference in
biochemical parameters including fasting blood glucose,
glycated hemoglobin A1c, total cholesterol, or triglyceride
between metformin and non-metformin (i.e., gliclazide,
acarbose, or repaglinide) treated type 2 diabetic patients.
Table 1 Changes in blood pressure, hepatic and renal biochemistry between metformin and non-metformin groups
Variables Metformin Non-metformin P value
Mean ± SD N Mean ± SD N
Blood glucose (mmol/L) 6.41 ± 0.98 112 6.33 ± 0.90 169 0.4993
Systolic blood pressure (mmHg) 133.29 ± 11.24 112 134.63 ± 9.43 169 0.2718
Diastolic blood pressure (mmHg) 73.69 ± 7.23 112 74.22 ± 6.78 169 0.5271
Hemoglobin A1c (%) 6.40 ± 0.57 112 6.29 ± 0.60 169 0.1260
Body mass index 25.66 ± 3.64 112 25.18 ± 3.43 169 0.2584
Total cholesterol (mmol/L) 4.71 ± 1.26 112 4.61 ± 0.90 169 0.4265
Triglyceride
(mmol/L)
1.90 ± 1.27 112 1.58 ± 0.99 169 0.0205
HDL(mmol/L) 1.13 ± 0.30 87 1.16 ± 0.32 59 0.5051
LDL (mmol/L) 2.66 ± 0.82 112 2.76 ± 0.81 169 0.3443
VLDL (mmol/L) 0.81 ± 0.41 87 0.69 ± 0.45 59 0.0988
Creatinine (μmol/L) 83.02 ± 17.49 112 85.89 ± 32.90 169 0.3979
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Changes in IL-6, IL-10, and TNF-α in serum between met-
formin and non-metformin groups
To determine any differences in cytokines in serum
from patients treated with metformin and non-
metformin treated type 2 diabetic patients, we mea-
sured the levels of IL-6, TNF-α, and IL-10 (Fig. 1a-c).
We found that there were no significant differences
in levels of TNF-α or IL-10 in serum between metfor-
min and non-metformin treated type 2 diabetic
patients. However, the levels of IL-6 were significant
reduced in serum of metformin-treated patients as
compared to non-metformin treated patients. These
results suggest that metformin has a specific effect on
pro-inflammatory mediators in type 2 diabetic
patients.
Changes in MCP-1 in urine between metformin and non-
metformin groups
Urinary cytokine might be useful for the early diagno-
sis and management of patients with diabetic ne-
phropathy [16, 17]. Hence, we measured the MCP-1
levels in urine of patients treated with metformin and
non-metformin (i.e., gliclazide, acarbose, or repagli-
nide). We found that the levels of MCP-1 were signifi-
cantly reduced in urine of metformin-treated patients
as compared to non-metformin group (Fig. 1d). These
results indicate that metformin has an inhibitory influ-
ence on urinary cytokine in type 2 diabetic patients.
Comparison of metformin with other individual drugs on
cytokines
To further determine the effects of metformin on cyto-
kines as compared to individual drug, we analyzed the
levels of cytokines in serum and urine of patients
treated with metformin, gliclazide, acarbose, and repa-
glinide. As shown in Table 2, the levels of IL-6 and
TNF-α in serum were significantly reduced by metfor-
min as compared to acarbose and repaglinide, whereas
there are no changes in serum IL-10 among these treat-
ments. Compared to gliclazide and repaglinide, metfor-
min treatment significantly reduced MCP-1 levels in
urine. Altogether, metformin reduces the levels of in-
flammatory cytokines as compared to individual glicla-
zide, acarbose, and repaglinide treatment.
Effects of metformin with different durations on cytokines
To determine the durations of metformin on cytokines
in serum and urine, we divided the type 2 diabetic pa-
tients into two groups (<1-year and > 1-year of metfor-
min treatment). No changes in biochemistry were
observed between these two groups of patients (Table 3).
There was no effect of serum IL-6, TNF-α, or urinary
MCP-1 levels between <1-year and >1 year treatments
with metformin in type 2 diabetic patients (Fig. 2). The
levels of IL-10 were increased in patients treated with
metformin for more than 1 year compared to less than
1 year (Fig. 2). These data indicate that metformin has
Table 2 Comparison of metformin with other drugs on cytokines
Treatment N Serum (pg/ml) Urine (pm/ml)
IL-6 IL-10 TNF-α MCP-1
Metformin 54 11.27 ± 2.56 2.50 ± 0.59 11.26 ± 2.14 111.28 ± 21.06
Gliclazide 44 12.24 ± 2.42 2.55 ± 0.69 10.89 ± 2.26 126.42 ± 28.85**
Acarbose 18 12.99 ± 2.73* 2.19 ± 0.74 12.62 ± 3.17* 114.24 ± 22.86
Repaglinide 36 13.02 ± 2.78** 2.56 ± 0.62 11.36 ± 1.98 123.46 ± 14.30**
*P < 0.05
**P < 0.01, vs metformin
Fig. 1 Effect of metformin on cytokines in serum and urine of patients with type 2 diabetes. Serum and urine were collected from 112 metformin
(Met.)-treated and 169 non-metformin-treated type 2 diabetic patients for cytokine measurement (a, IL-6; b, IL-10; c, TNF-α; d, MCP-1) by ELISA.
Data were shown as Mean ± SD. **P < 0.01, ***P < 0.001, vs metformin group
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an anti-inflammatory property in a duration-dependent
manner.
Effects of metformin with different doses on cytokines
To determine the doses of metformin on cytokines in
serum and urine, we divided the type 2 diabetic patients
into two groups (1000 and 1500 mg of metformin treat-
ment). No significant changes in biochemistry were ob-
served between these two groups of patients (Table 4).
We found that there were no effects of serum IL-6, IL-
10, or TNF-α between 1000 and 1500 mg treatments
with metformin in type 2 diabetic patients (Fig. 3).
However, urinary MCP-1 levels were significantly re-
duced in patients treated with metformin at 1500 mg as
compared to 1000 mg of metformin treatment (Fig. 3).
These results indicate that metformin reduces inflam-
matory responses in a dose-dependent manner.
Discussion
In the present study, we found that metformin treat-
ment has specific effects on cytokines (serum IL-6 and
urinary MCP-1) as compared to the non-metformin
(i.e., gliclazide, acarbose, or repaglinide) treatment type
2 diabetic patients. When compared to individual gli-
clazide, acarbose, or repaglinide treatment, metformin
significantly reduced the pro-inflammatory cytokines in
serum and urine. In addition, metformin reduced in-
flammatory responses in a duration- and dose-
dependent manner in patients with type 2 diabetes.
These findings suggest that metformin (1000 mg, q.d.)
for 1 year has beneficial effects to reduce inflammatory
responses in systemic circulation and urine in type 2
diabetic patients.
In addition to diet control and exercise, type 2 diabetic
patients commonly require diabetes medications and insu-
lin. The most commonly prescribed medication for type 2
diabetes is metformin with less side-effect of
hypoglycemia. As compared to gliclazide, acarbose, or
repaglinide, there were no significant changes in biochem-
ical parameters for hepatic and renal function. These re-
sults suggest that the medications including metformin
for type 2 diabetic patients in this study are safe.
Fig. 2 Effect of metformin with different durations on cytokines in serum and urine of patients with type 2 diabetes. Serum and urine were
collected from type 2 diabetic patients treated with metformin for less (n = 71) and more than 1 year (n = 41) for cytokine measurement by ELISA.
Data were shown as Mean ± SD. **P < 0.05, vs metformin (<1 year) group
Table 3 Effect of metformin with different durations on blood biochemistry
Variables Duration (<1 year) Duration (>1 year) P value
Mean ± SD N Mean ± SD N
Blood glucose (mmol/L) 6.45 ± 1.00 71 6.35 ± 0.95 41 0.6092
Systolic blood pressure (mmHg) 132.21 ± 9.76 71 135.17 ± 13.35 41 0.1807
Diastolic blood pressure (mmHg) 73.56 ± 6.89 71 73.90 ± 7.86 41 0.8122
Hemoglobin A1c (%) 6.39 ± 0.56 71 6.41 ± 0.59 41 0.8255
Body mass index 25.51 ± 3.04 71 25.93 ± 4.53 41 0.5601
Total cholesterol (mmol/L) 4.81 ± 1.44 71 4.55 ± 0.87 41 0.3038
Triglyceride (mmol/L) 1.12 ± 0.34 71 2.09 ± 1.49 41 0.0400
HDL (mmol/L) 1.12 ± 0.34 36 1.15 ± 0.23 23 0.7767
LDL (mmol/L) 2.65 ± 0.83 71 2.69 ± 0.81 41 0.7920
VLDL (mmol/L) 0.83 ± 0.39 36 0.77 ± 0.44 23 0.5596
Creatinine (μmol/L) 80.75 ± 15.11 71 86.95 ± 20.59 41 0.0703
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A variety of mechanisms contribute to defective insulin
secretion and responses in type 2 diabetes, which includ-
ing glucotoxicity, lipotoxicity, oxidative stress, and the for-
mation of amyloid deposits in the islets [18, 19].
Interestingly, all of these mechanisms are associated with
inflammatory responses [20]. This is corroborated by
the findings that chronic inflammatory responses play
important roles in the pathogenesis of type 2 diabetes
by causing islet dysfunction and insulin resistance in
both inflammasome-dependent or -independent man-
ners [21]. Therefore, the ideal anti-diabetic drugs
would be possessing anti-inflammatory properties in
addition to reducing glucose in blood. In comparison
with gliclazide, acarbose, and repaglinide, metformin
reduced the levels of serum IL-6, TNF-α, and urinary
MCP-1 in patients with type 2 diabetes. In addition,
metformin exhibits a specific effect on inflammatory
responses at the different doses and durations. Altogether,
these findings suggest that metformin exhibits anti-
diabetic effects by reducing both glucose levels and
inflammatory responses.
It is well-known that metformin treatment in diabetic
patients with chronic kidney diseases would be cautious, as
it causes lactic acidosis in the setting of renal dysfunction
[22, 23]. In our study, we did not find any abnormalities of
renal function in these diabetic patients treated with
metformin or non-metformin. Future studies are required
to determine how metformin reduces MCP-1 reduction in
urine without changes in renal function. In addition, the
disadvantage of this study is unable to determine the
effects of metformin or other anti-diabetic drugs on
inflammatory responses through a longitudinal manner.
Conclusion
Metformin reduces inflammatory responses in addition to
glucose reduction in type 2 diabetic patients. There are
specific effects on cytokines (serum IL-10 and urinary
MCP-1) by the different durations and doses of metformin
in patients with type 2 diabetes. Therefore, metformin re-
duces inflammatory responses in systemic circulation and
urine, which contributes to its beneficial effects on type 2
diabetes.
Fig. 3 Effect of metformin with different doses on cytokines in serum and urine of patients with type 2 diabetes. Serum and urine were collected
from type 2 diabetic patients treated with metformin with 1 g (n = 91) and 1.5 g (n = 21) for cytokine measurement by ELISA. Data were shown
as Mean ± SD. ***P < 0.001, vs metformin (1 g) group
Table 4 Effect of metformin with different doses on blood biochemistry
Variables Metformin (1000 mg) Metformin (1500 mg) P value
Mean ± SD N Mean ± SD N
Blood glucose (mmol/L) 6.44 ± 0.96 91 6.27 ± 1.04 21 0.4684
Systolic blood pressure (mmHg) 133.67 ± 11.16 91 131.67 ± 11.70 21 0.4640
Diastolic blood pressure (mmHg) 73.10 ± 6.73 91 76.24 ± 8.81 21 0.0727
Hemoglobin A1c (%) 6.36 ± 0.57 91 6.55 ± 0.58 21 0.1797
Body mass index 25.64 ± 3.52 91 25.75 ± 4.23 21 0.8989
Total cholesterol (mmol/L) 4.68 ± 1.36 91 4.85 ± 0.76 21 0.5970
Triglyceride (mmol/L) 2.00 ± 1.38 91 1.48 ± 0.45 21 0.0940
HDL(mmol/L) 1.13 ± 0.31 46 1.15 ± 0.30 13 0.7942
LDL (mmol/L) 2.58 ± 0.83 91 3.03 ± 0.66 21 0.0212
VLDL (mmol/L) 0.82 ± 0.42 46 0.75 ± 0.38 13 0.5954
Creatinine (μmol/L) 82.07 ± 15.98 91 87.14 ± 22.93 21 0.2321
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